Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health PTH Calcium Phosphate Coverage Update…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage and reimbursement guidance for laboratory testing of parathyroid hormone (PTH), phosphorus, calcium, and magnesium for Oscar Health members, including indications, frequency limits for CKD and related disorders, and tests considered not meeting criteria.

    Policy Summary
    PayerOscar Health
    PolicyParathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDocument clinical indication and supporting labs (e.g., serum calcium, PTH, creatinine, 25‑OH vitamin D) when ordering PTH or related tests to meet medical necessity.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 moPTH testing frequency for Grade 3 CKD
    3 moPTH testing frequency for Grade 4–5 CKD
    Not coveredTruncated PTH metabolites
    Not coveredRoutine wellness electrolyte testing

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    7Procedure codes listed
    8Guideline sources cited

    Coverage Criteria for PTH, Phosphorus, Calcium, and Magnesium Testing

    Serum intact PTH — Medically necessary indications

    Covered when ANY of the following are met:

    PTH_Covered_Indications: a) Individuals with abnormal calcium levels.

    from policy indications

    PTH_Covered_Indications: b) Initial assessment and diagnosis of hypoparathyroidism for individuals with signs of hypoparathyroidism.

    see Note 1 in policy

    PTH_Covered_Indications: c) Individuals with osteoporosis or low bone mass.

    policy lists osteoporosis/low bone mass

    PTH_Covered_Indications: d) Individuals who have undergone parathyroidectomy.

    postoperative monitoring indication

    PTH_Covered_Indications: e) Chronic kidney disease (CKD) monitoring frequency: (i) Grade 3 CKD: one test every 12 months; (ii) Grade 4 or Grade 5 CKD: one test every 3 months.Grade 3: every 12 months; Grade 4–5: every 3 months

    policy frequency limits for CKD

    PTH_Covered_Indications: f) Pseudohypoparathyroidism or related disorders monitoring frequency: (i) age <18 years: one test every 3 months; (ii) age ≥18 years: one test every 12 months.<18: every 3 months; ≥18: yearly

    per international consensus recommendations referenced in policy

    PTH_Covered_Indications: g) Annual testing for individuals diagnosed with hyperparathyroidism who have not undergone parathyroidectomy.annual

    policy stated annual testing for untreated hyperparathyroidism

    PTH_Covered_Indications: h) Annual testing for individuals with multiple endocrine neoplasia type 2A (MEN2A) or familial medullary thyroid carcinoma.annual

    policy lists MEN2A / familial MTC

    Routine/wellness testing — Not medically necessary

    Not covered for asymptomatic wellness visits or general exams without abnormal findings:

    Wellness_Not_Covered: Serum, blood, or fecal magnesium testing; serum phosphorus/phosphate testing; urine phosphorus/phosphate testing; serum total calcium, serum ionized calcium, or urine calcium testing are not medically necessary when performed for wellness or general exams without abnormal findings.

    explicitly listed in policy

    Guideline-aligned diagnostic and monitoring criteria

    Coverage aligned with guideline-recommended testing when diagnostic or monitoring criteria are met:

    Evaluation of suspected primary hyperparathyroidism: Include serum total calcium, PTH, creatinine, and 25-hydroxyvitamin D as part of the biochemical evaluation; consider 24-hour urine calcium and creatinine when familial hypocalciuric hypercalcemia or hypercalciuria is a concern.

    AAES recommendation 1-1 and 1-2; see AAES chunks

    Post-parathyroidectomy assessment: Assess cure and complications with longitudinal testing including calcium, PTH, and 25-hydroxyvitamin D for at least 6 months; failure to normalize PTH by 6 months may indicate persistent disease.6 months

    AAES recommendations on postoperative assessment

    Pseudohypoparathyroidism and PTH resistance monitoring: Measure PTH, calcium, phosphorus, and calcifediol at diagnosis and regularly thereafter (every 6 months in children and at least yearly in adults); monitor more frequently if symptomatic, during growth, pregnancy, or intercurrent illness.

    CKD monitoring (KDIGO)

    KDIGO — Monitoring of calcium, phosphate, and PTH by CKD stage

    CKD stage-based monitoring: Measure serum calcium, phosphate, and PTH beginning in CKD G3a. Frequency by stage: G3a–G3b calcium/phosphate every 6–12 months with PTH once and then as indicated by baseline and progression; G4 calcium/phosphate every 3–6 months and PTH every 6–12 months; G5 calcium/phosphate every 1–3 months and PTH every 3–6 months. Use serial measurements together to guide treatment.see KDIGO tables

    KDIGO recommendations and monitoring intervals

    Kidney transplant monitoring (NKF KDOQI)

    NKF KDOQI — Post-kidney transplant monitoring

    Post-transplant monitoring: Measure calcium, phosphorus and PTH frequently after transplant: during the first 3 months measure calcium and phosphorus every 2 weeks then monthly; measure PTH monthly for the first 3 months then every 3 months. In the first week after transplant, measure phosphorus daily; treat persistent phosphate <2.5 mg/dL with supplementation. After 1 year, follow CKD-stage monitoring tables based on kidney function.phosphate <2.5 mg/dL

    NKF KDOQI transplant timing and supplementation guidance

    PHPT diagnostic criteria (NICE)

    NICE — Primary hyperparathyroidism (PHPT) diagnostic testing

    Primary hyperparathyroidism diagnostic triggers: Measure albumin-adjusted serum calcium in primary care for patients with features of hypercalcaemia (eg, thirst, polyuria, constipation), osteoporosis, fragility fracture, or renal stone, or an incidental elevated albumin-adjusted calcium (≥2.6 mmol/L). Repeat albumin-adjusted calcium at least once if initial result is ≥2.6 mmol/L or ≥2.5 mmol/L with features. Measure PTH when albumin-adjusted calcium is ≥2.6 mmol/L on two separate occasions, or ≥2.5 mmol/L on two separate occasions with features; PTH sample must be random and concurrent with albumin-adjusted calcium. Repeat PTH measurements are not routinely required in primary care.albumin-adjusted calcium ≥2.6 mmol/L (or ≥2.5 mmol/L with features)

    NICE PHPT guideline statements

    Hypoparathyroidism diagnosis and monitoring (ESE, ASBMR)

    ESE / ASBMR — Hypoparathyroidism monitoring and diagnosis

    Chronic HypoPT diagnosis: Diagnosis confirmed by hypocalcaemia with low/undetectable or inappropriately normal intact PTH on two occasions at least two weeks apart; assess phosphorus, magnesium, 1,25(OH)2D and urinary fractional calcium as supportive findings. Postsurgical HypoPT is considered permanent if persisting >12 months.two occasions ≥2 weeks apart

    ASBMR and ESE diagnostic criteria

    HypoPT monitoring intervals: Routine biochemical monitoring of ionised or albumin-adjusted calcium, phosphate, magnesium, and creatinine every ~3–6 months; 24-hour urinary calcium every 1–2 years in stable patients. During pregnancy/lactation monitor ionised/albumin-adjusted calcium every 3–4 weeks and more frequently (eg, weekly) around delivery.every 3–6 months (routine); pregnancy 3–4 weeks (weekly near delivery)

    ESE/ASBMR monitoring recommendations

    Cancer-related laboratory monitoring (NCCN)

    NCCN — Cancer-related testing where applicable

    Tumor lysis and therapy monitoring: For malignancies and therapies with tumor lysis risk (eg, initial workup for ALL; CLL/SLL receiving venetoclax), monitor blood chemistries including phosphorus and calcium as part of TLS panels; during venetoclax ramp-up perform pre-dose and serial post-dose chemistries per NCCN tables. Denosumab therapy requires periodic serum calcium monitoring and vitamin D/calcium repletion.per NCCN TLS monitoring table

    NCCN TLS and therapy-specific monitoring guidance

    Bone lesion workup: When evaluating bone tumors (eg, giant cell tumor of bone), consider measuring serum calcium, phosphate and PTH to exclude brown tumor of hyperparathyroidism as a differential diagnosis.clinical suspicion

    NCCN recommendation for bone cancer workup

    Phosphate binder monitoring (NICE)

    NICE — Phosphate binder therapy monitoring

    Phosphate binder monitoring: For CKD patients on phosphate binders, assess serum phosphate control at routine clinical reviews and consider changes in serum calcium when selecting or adjusting binders; if serum calcium increases toward or above the age‑adjusted upper limit, investigate other causes and consider reducing or switching from calcium‑based binders.rising serum calcium toward/above age-adjusted upper limit

    NICE recommendations on binder selection and review

    Guideline-derived monitoring recommendations

    Guideline-based monitoring recommendations referenced in this section (examples by condition):

    CKD monitoring: NICE does not recommend routinely measuring calcium, phosphate, PTH and vitamin D in people with eGFR ≥30 mL/min/1.73 m2 (GFR categories G1–G3); measure serum calcium, PTH and phosphate for GFR categories G4 or G5 and determine frequency by values and clinical circumstances.GFR categories G4/G5

    NICE guidance

    Chronic hypoparathyroidism monitoring: ESE recommends routine biochemical monitoring of ionized or albumin-adjusted calcium, phosphate, magnesium, and creatinine every 3–6 months; in patients on conventional therapy, monitor 24‑hour urinary calcium every 1–2 years. Pregnancy/lactation require more intensive monitoring per ESE.every 3–6 months for blood tests; 1–2 years for 24-hour urine calcium

    ESE consensus

    Bisphosphonate therapy: ASCO/CCO recommend measuring serum calcium prior to initiating bisphosphonate therapy and monitoring serum calcium and renal function during treatment (eg, IV zoledronic acid).

    Testing serum for truncated parathyroid hormone (PTH) metabolites (for example, amino‑terminal and carboxy‑terminal fragments) does not meet criteria. The policy states these assays are not supported because of a lack of published scientific literature demonstrating clinical benefit or necessity.

    The policy discourages routine, blanket electrolyte testing in the emergency department for patients without documented risk factors. A retrospective ED study noted that clinical decision tools could identify patients at low risk for abnormal calcium and magnesium, and that testing only patients with risk factors would miss very few clinically significant abnormalities. Ordering electrolytes (Ca, Mg, PO4) without risk factors may therefore be considered over‑testing.

    NICE guidance cited in the policy recommends that clinicians do not routinely measure calcium, phosphate, PTH, and vitamin D in people with an estimated GFR of ≥30 mL/min/1.73 m2 (GFR categories G1–G3). NICE instead recommends measuring these tests for patients in GFR categories G4 or G5 and determining subsequent testing frequency by measured values and clinical circumstances.

    The policy references specialty guidance that advises against routine serum magnesium testing in certain populations. The SOGC (2014) guideline explicitly states that routine monitoring of serum magnesium in pregnancy is not recommended. Similarly, AGA guidance on chronic constipation indicates routine metabolic testing (including calcium) is not recommended in the absence of other clinical features; these sources support limited, indication‑based magnesium testing in pregnancy and pediatrics rather than universal screening.

    This policy lists multiple evidence references and guideline sources (for example KDIGO, NKF KDOQI, NICE, ESE, AAES, AGA and NCCN) underpinning coverage and monitoring recommendations. The referenced sections provide the guideline context used to determine when testing is appropriate; the cited chunks do not, however, specify additional explicit exclusions beyond the not‑medically‑necessary items already listed in the policy.

    Summary of tests considered not to meet criteria in this policy: serum truncated PTH metabolites (amino‑ and carboxy‑terminal fragments) are expressly listed as not meeting criteria, and routine metabolic testing during wellness or general exams — including serum magnesium, phosphorus, urine phosphorus, and serum or urine calcium — does not meet criteria when performed without abnormal findings.

    Evidence cited suggests that indiscriminate electrolyte testing in the emergency department identifies very few additional clinically significant abnormalities: in one ED study, restricting calcium and magnesium testing to patients with clinical risk factors would have missed only about 1% of cases, supporting more selective testing in low‑risk presentations.

    NICE guidance in the policy clarifies a GFR threshold for routine measurement: do not routinely test calcium, phosphate, PTH and vitamin D in people with eGFR ≥30 mL/min/1.73 m2 (G1–G3). Measurement is recommended for GFR categories G4 or G5, with subsequent testing frequency determined by results and clinical circumstances.

    The policy cites guideline statements that routine metabolic testing is low yield in certain low‑risk clinical contexts. For example, the AGA (2013) recommends against routine metabolic testing (including serum calcium) for chronic constipation without other features, and SOGC guidance (2014) advises against routine serum magnesium monitoring in pregnancy—supporting an approach of testing only when clinical features warrant it.

    Within the provided policy excerpts there are no additional explicit not‑medically‑necessary conditions named beyond those already listed (truncated PTH fragments and routine wellness/general exam metabolic testing). The referenced evidence and guideline lists support the policy recommendations but do not create further exclusions in these chunks.

    Applicable Procedure Codes and Key Values

    Reference and critical values
    24-hour urine calcium reference (males)<250 mg/24 hours
    24-hour urine calcium reference (females)<200 mg/24 hours
    Serum magnesium critical/safety thresholdSerum Mg >9 mg/dL can be life‑threatening
    Albumin-adjusted serum calcium thresholds for PTH measurement
    Albumin-adjusted calcium threshold — high triggerMeasure PTH when albumin-adjusted serum calcium ≥2.6 mmol/L on two separate occasions
    Albumin-adjusted calcium threshold — lower trigger with featuresMeasure PTH when albumin-adjusted serum calcium ≥2.5 mmol/L on two separate occasions if clinical features of PHPT are present

    Provider Responsibilities, Prior Authorization, and Documentation

    Prior Authorization

    Authorization and medical necessity required

    Services must meet authorization and medical necessity guidelines for the procedure, diagnosis, and the member's benefit coverage at the time of the request. Providers are responsible for accurate submission of documentation and appropriate coding; failure to follow coding/billing guidelines or reimbursement policies may result in claim denial or recoupment.

    • Confirm member benefits and authorization requirements before ordering tests.
    • Include clinical indication and relevant diagnostic data to support medical necessity on the claim.
    Prior Authorization

    No payer prior authorization specified

    The policy text does not state any payer-specific prior authorization requirement for PTH, calcium, phosphate, or magnesium testing; clinical guidelines and the policy's coverage criteria should be used to justify testing when documentation is requested.

    • No explicit payer prior authorization rule is listed in the document chunks cited.

    Clinical Background and Rationale

    Parathyroid hormone (PTH), calcitriol and FGF23 are central regulators of calcium and phosphate homeostasis. PTH rapidly raises serum calcium through bone resorption and renal effects, while calcium circulates largely protein‑bound with approximately 45% ionized (active) fraction. PTH has a short half‑life and circulating truncated fragments can complicate measurement, which underlies the policy’s emphasis on using intact PTH assays and avoiding unsupported fragment assays.

    Definitions and Measurement Considerations

    iPTH — Intact parathyroid hormone
    DefinitionIntact parathyroid hormone (iPTH) — the circulating PTH molecule measured by intact assays, reflecting the biologically active hormone and its immunoreactive forms
    Clinical roleRegulates serum ionized calcium via bone resorption and renal reabsorption; short half-life (~2–4 minutes)
    Measurement caveatProteolytic truncated PTH fragments can comprise a large proportion of circulating immunoreactive PTH and interfere with some assays
    PO43- (phosphate)
    TermPO4(3-) (phosphate) — phosphorus in its oxidized phosphate polyatomic ionic form measured in plasma or urine
    Clinical notesInorganic phosphates are hormonally regulated (primarily by PTH) and are commonly measured in blood; urine testing is less common

    Policy Revision History

    2026-10-01Effective dateLatest

    Policy became effective on 2026-10-01.

    2026-06-16Last review

    Policy was last reviewed on 2026-06-16.

    2026-06-16Publication action

    Publication action recorded on 06/16/2026.

    Policy Summary
    PayerOscar Health
    PolicyParathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDocument clinical indication and supporting labs (e.g., serum calcium, PTH, creatinine, 25‑OH vitamin D) when ordering PTH or related tests to meet medical necessity.
    SourceLink
    On This Page
    Coverage Criteria for PTH, Phosphorus, Calcium, and Magnesium TestingApplicable Procedure Codes and Key ValuesProvider Responsibilities, Prior Authorization, and DocumentationClinical Background and RationaleDefinitions and Measurement ConsiderationsPolicy Revision History
    every 6 months (children); >= yearly (adults)

    First International Consensus and EuroPHPnet recommendations

    Diagnosis of normocalcemic PHPT: Persistently normal albumin-adjusted total and ionized serum calcium with elevated PTH on at least two consecutive measurements over a 3–6 month period meets criteria for normocalcemic primary hyperparathyroidism.2 measurements over 3-6 months

    International Workshop definition

    prior to initiation and throughout treatment

    ASCO/CCO recommendation

    Osteoporosis secondary causes evaluation: AACE/ACE recommends assessment including intact PTH, phosphate, 25‑OH vitamin D, and 24‑hour urine calcium when evaluating secondary causes of osteoporosis; perform urine testing after vitamin D repletion and adequate calcium intake.after vitamin D repletion and adequate calcium intake

    AACE/ACE guidance

    Post-thyroidectomy monitoring: Multisociety consensus and ATA recommend measuring PTH within 1–24 hours after thyroidectomy and measuring serum calcium (albumin‑adjusted and/or ionized); start oral calcium with or without active vitamin D in patients with biochemical hypoparathyroidism before discharge.PTH measured within 1-24 h post-op

    2025 multisociety consensus and ATA statements

    Heart failure initial evaluation: 2022 AHA/ACC/HFSA guideline includes serum calcium and magnesium as part of standard laboratory evaluation in patients with heart failure.standard diagnostic evaluation

    AHA/ACC/HFSA guideline inclusion

    Pregnancy with HypoPT: ESE recommends monitoring ionized and/or albumin-adjusted calcium regularly (eg, every 3–4 weeks) during pregnancy and lactation and more frequently around delivery to keep calcium at the lower end of normal.every 3-4 weeks (more frequent near delivery)

    ESE pregnancy monitoring guidance

    Sample timing requirementPTH sample should be random and concurrent with albumin-adjusted serum calcium measurement
    Post-transplant phosphate
    Post-transplant phosphate monitoringMeasure phosphorus daily during first week after transplant; then frequently per transplant schedule
    Supplementation thresholdPersistently low serum phosphate <2.5 mg/dL should be treated with phosphate supplementation
    Follow-up after 1 yearAfter first year, follow longer-term testing frequency per CKD stage tables
    Prior Authorization

    Use guideline triggers to justify testing if requested

    Although no explicit prior authorization rules are given, guideline-based triggers (for example CKD stage thresholds or NICE albumin-adjusted calcium thresholds) are the documented justification clinicians should cite if prior authorization or medical necessity documentation is requested.

    • Use CKD/KDIGO stage-based monitoring intervals or NICE calcium thresholds as justification when supporting testing.
    Prior Authorization

    No explicit prior authorization requirement listed

    The document contains no explicit requirement that prior authorization must be obtained for these tests; ordering clinicians should follow member benefit rules and applicable payer processes where present.

    • If a conflict exists between this policy and government coverage (e.g., Medicare LCD/NCD), the government policy governs determinations.
    Prior Authorization

    Prior authorization not specified in these sections

    Review of the provided policy chunks found no additional prior authorization requirements specified for PTH, phosphate, calcium, or magnesium testing in these sections.

    • Proceed based on coverage criteria and member-specific benefit/contract rules.
    Note
    Step Therapy

    Observe guideline monitoring cadence before escalation

    Follow guideline-recommended monitoring cadence before escalating therapy: for pseudohypoparathyroidism and related disorders measure PTH, calcium, and phosphorus every 6 months in children and at least yearly in adults, with more frequent monitoring for symptomatic patients, during growth, pregnancy, or acute illness.

    • Children: every 3–6 months (guideline examples cite every 3–6 months for some recommendations).
    • Adults: at least yearly unless clinically indicated for more frequent monitoring.
    Step Therapy

    Monitor calcium when using phosphate binders

    When phosphate binders are prescribed for CKD patients, monitor serum phosphate and calcium at routine clinical reviews and reconsider calcium-based binder choice if serum calcium rises toward or above the age-adjusted upper normal limit.

    • Assess phosphate control at each routine review and consider switching or reducing calcium-based binders if calcium rises.
    Note
    Step Therapy

    No step therapy specified

    No step therapy requirements are specified in the cited document chunks for PTH, calcium, phosphate, or magnesium testing or related treatments.

    • Manage testing and treatment based on clinical guidelines and individualized patient needs.
    Documentation Required

    Submit accurate documentation and standard coding

    Providers must submit accurate clinical documentation and code according to industry-standard coding guidelines (CPT, HCPCS, ICD-10, etc.); failure to follow coding/billing guidance may result in denial or recoupment.

    • Include clinical indication and supporting lab values/diagnoses on the claim.
    • Use standard coding resources and follow CMS/CCI guidance where applicable.
    Documentation Required

    Document required labs and timing for pHPT workup

    For evaluation of suspected primary hyperparathyroidism, document serum total calcium, PTH, creatinine, and 25-hydroxyvitamin D; consider documenting timing of measurements and follow-up plans (for example, 6-month assessment of cure after parathyroidectomy).

    • Include 24-hour urine calcium and creatinine when familial hypocalciuric hypercalcemia or hypercalciuria is a concern.
    • Document timing of post-parathyroidectomy longitudinal testing (assess cure at 6 months).
    Documentation Required

    Document CKD stage, GFR, and transplant timing for serial testing

    When ordering serial calcium, phosphate, and PTH testing for CKD or transplant patients, document CKD stage, estimated GFR, baseline values, and time since transplant because recommended monitoring frequency differs by stage and time post-transplant.

    • For transplant recipients, document time since transplant (e.g., first 3 months monitoring is more frequent: calcium/phosphate every 2 weeks; PTH monthly).
    • Use KDIGO/NKF KDOQI monitoring tables to support frequency documented.
    Documentation Required

    Document treatment modality and pregnancy/lactation status for HypoPT

    For chronic hypoparathyroidism, document the treatment modality and pregnancy or lactation status because monitoring frequency recommendations differ (routine monitoring every ~3–6 months; pregnancy monitoring every 3–4 weeks and more frequently around delivery).

    • Note therapy type (conventional therapy, recombinant PTH, supplements) and plan for urinary calcium monitoring if on conventional therapy.
    Billing Rule

    Document and bill using the listed procedure codes

    Use applicable CPT/HCPCS procedure codes when documenting and billing tests: 82310, 82330, 82340, 83735, 83970, 84100, and 84105 are listed as the relevant procedure codes in the policy.

    • 82310 — Calcium; total
    • 82330 — Calcium; ionized
    • 82340 — Calcium; urine quantitative, timed specimen
    • 83735 — Magnesium
    • 83970 — Parathormone (parathyroid hormone)
    • 84100 — Phosphorus inorganic (phosphate)
    • 84105 — Phosphorus inorganic (phosphate); urine
    Documentation Required

    Cite guideline and evidence references to support documentation

    The policy includes numerous evidence references and guideline sources (KDIGO, NICE, AAES, ESE, NKF KDOQI, etc.) that can be cited to support medical necessity and clinical rationale in documentation, though no specific submission format is mandated.

    • Reference the named guideline (e.g., KDIGO, NICE, AAES) appropriate to the clinical context in clinical notes when justifying testing frequency or indications.
    Denial Risk

    Denial risk for improper coding or lack of medical necessity

    Claims may be denied if coding/billing guidelines or reimbursement policies are not followed and if services do not meet authorization and medical necessity criteria; ensure documentation clearly links the test to a covered indication.

    • Include specific covered indication from policy (for example: abnormal calcium, CKD stage with stated frequency, hypoparathyroidism evaluation).
    Denial Risk

    Over-testing risk in emergency setting

    Testing electrolytes (calcium, magnesium, phosphate) in the emergency department without documented risk factors may be considered over-testing; authors of a cited ER study found patients without risk factors were unlikely to have clinically significant abnormalities.

    • Use documented risk factors or clinical decision tools to support ED electrolyte testing to reduce over-testing and potential denials.
    Prior Authorization

    Follow NICE albumin-adjusted calcium thresholds before PTH testing

    Per NICE, measure PTH only when albumin-adjusted serum calcium meets the guideline thresholds: PTH is recommended if albumin-adjusted calcium is ≥2.6 mmol/L on at least two separate occasions, or ≥2.5 mmol/L on at least two occasions when features of PHPT are present; when measuring PTH a random sample concurrent with albumin-adjusted calcium is required.

    • Repeat albumin-adjusted calcium in primary care if initial result is ≥2.6 mmol/L, or ≥2.5 mmol/L with features, before measuring PTH.
    Note

    Follow applicable government coverage policies when they supersede

    If there is a conflict between this policy and any applicable government policy (for example Medicare LCDs/NCDs or state Medicaid), the government policy will be used to make the determination; providers should verify and follow the most up-to-date government guidance when applicable.

    • Check CMS LCD/NCD and state Medicaid rules for any member with Medicare/Medicaid coverage prior to ordering/testing.
    Denial Risk

    No discrete denial triggers specified in these chunks

    The cited document chunks do not list specific denial triggers beyond general statements; no discrete denial rules are specified in these sections.

    • Use the policy's covered indications and guideline criteria to reduce risk of unsupported testing.
    Biological roleImportant component of biomolecules and cellular buffers; relevant to bone and renal health
    Third-generation PTH assay
    DefinitionThird-generation PTH assay — an immunoassay designed to measure full-length biologically active PTH (1-84) with improved specificity over earlier intact assays
    Performance noteShown to accurately measure PTH(1-84) and remain stable in plasma/serum at room temperature for ~24–27 hours depending on sample type
    Clinical implicationReduces cross-reactivity with truncated inactive fragments that can confound earlier assays
    Corrected calcium — albumin-adjusted formula
    Corrected calcium formulaCorrected Ca = total serum calcium (mg/dL) + 0.8 × (4.0 − serum albumin [g/dL])
    Preferred useAlbumin-adjusted total calcium is recommended over routine use of ionized calcium in many centers due to limited ionized testing capability
    ContextUsed in evaluation and monitoring of primary hyperparathyroidism and postoperative care
    Chronic hypoparathyroidism (HypoPT)
    Diagnostic criteriaChronic hypoparathyroidism (HypoPT) is confirmed by hypocalcaemia with low/undetectable or inappropriately normal intact PTH on two occasions at least two weeks apart
    Permanence after surgeryPostsurgical HypoPT is considered permanent if it persists more than 12 months after surgery
    Baseline labsBaseline evaluation includes albumin-adjusted or ionized calcium, magnesium, phosphorus, creatinine, 25(OH)D, and 24-hour urine calcium
    CKD-MBD monitoring definition (KDIGO)
    KDIGO monitoring scopeCKD-MBD monitoring — measure serum calcium, phosphate, PTH, and alkaline phosphatase beginning in CKD G3a (earlier in children)
    Frequency by stageFrequency varies by CKD stage (e.g., G3a–G3b calcium/phosphate every 6–12 months; G4 every 3–6 months; G5 calcium/phosphate every 1–3 months; PTH frequency also stage-dependent)
    Treatment decisionsTreatment should be based on serial assessments of phosphate, calcium, and PTH considered together
    Chronic hypoparathyroidism — ESE definition and recommendations
    ESE diagnostic statementConsider chronic HypoPT in patients with persistent hypocalcaemia and inappropriately low or inappropriately normal PTH; recommend genetic testing/family screening for nonsurgical cases
    Monitoring recommendationsRoutine biochemical monitoring of ionised or albumin-adjusted calcium, phosphate, magnesium, and creatinine every ~3–6 months; 24-hour urinary calcium every 1–2 years in stable patients
    Pregnancy guidanceDuring pregnancy and lactation monitor ionised/albumin-adjusted calcium every ~3–4 weeks and more frequently (eg, weekly) around delivery
    Postoperative biochemical hypoparathyroidism
    DefinitionPostoperative biochemical hypoparathyroidism — low PTH and/or low serum calcium detected after thyroidectomy
    Timing of measurementFirst postoperative PTH level recommended within 24 hours; measurement 1–6 hours after total thyroidectomy also advised by some societies
    Early managementStart oral calcium with or without active vitamin D in patients with biochemical hypoparathyroidism before discharge; repeat calcium measurements to guide supplementation
    PTH measurement considerations — assay variability, sampling and storage effects
    Assay variabilityPTH assays are affected by proteolytic fragments and differing assay specificities; third-generation assays improve specificity but differences across platforms remain
    Sampling and storage effectsSample type and storage matter: plasma is more stable than serum at room temperature; stability up to ~24–27 h reported for some assays
    Clinical implicationConsider assay generation, sample handling, and lab-specific reference ranges when interpreting PTH results, especially in CKD patients
    Clinical guideline sources — list of cited guideline documents
    KDIGOKidney Disease Improving Global Outcomes (KDIGO)
    NKF KDOQINational Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI)
    NICENational Institute for Health and Care Excellence (NICE)
    ESEEuropean Society of Endocrinology (ESE)
    ASBMR / AAES / ATAAmerican Society for Bone and Mineral Research (ASBMR), American Association of Endocrine Surgeons (AAES), American Thyroid Association (ATA)